Monday, June 30, 2025 6/30/2025

Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

Award Number: U10CA180863
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/06/2014
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network - Canadian Cancer Trials Group PI = Dancey, Janet US National Clinical Trials Network – Canadian Collaborating #CA180863 Clinical Trials Network ADMINISTRATIVE SUPPLEMENT 1 March 2025 – 28 February 2026 Project Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental reevaluation of clinical trial design and delivery to ensure maximal patient and societal benefits. The Canadian Cancer Trials Group (CCTG) has strong partnerships with US investigators and groups within the NCTN, which emphasize international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. As the Canadian Collaborating Clinical Trials Network (CCCTN) of the NCTN, CCTG expands NCTN’s scientific expertise by: 1) Involving the best and brightest within its network in NCTN leadership roles; 2) Increasing clinical trial capacity through its national network, which includes all centres in Canada; and, 3) Facilitates access to Canadian patients, which is particularly important for trials testing interventions in rare populations. CCTG contributes to scientific concept development, accrual, biospecimen collection, and network leadership, and has expertise in instrumental components of trial conduct (including information technology and regulations). CCTG develops and participates in NCTN adult cancer trial portfolios in breast, lung, urological, and gastrointestinal malignancies, in uncommon/rare settings of unmet need such as hematological, skin, brain and head and neck cancers, and includes adolescents and young adults on AYA trials. In addition, CCTG capitalizes on opportunities to extend its scope of trial activity to include surgical and lifestyle interventions and imaging and digital health endpoints. Research incorporates translational science and other correlative endpoints to enrich information derived from NCTN trials and methods and technology development to improve clinical trial designs, endpoints, and execution. Finally, CCTG contributes trial datasets from NCTN trials as part of its data sharing policy. As the CCCTN, CCTG, Canada’s largest and most experienced clinical trials unit, creates and delivers innovative strategies that arise from the NCTN accelerating the translation of scientific advances into improvements in cancer treatments improving the lives of children, adolescents, and adults diagnosed with cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,382,930 )
2025	2025	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	002	11	4/4/2025	SUPPLEMENT FOR EXPANSION	$1,383,033
2025	2024	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	000	11	1/6/2025	NON-COMPETING CONTINUATION	$0
2025	2023	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	001	9	2/4/2025	SUPPLEMENT FOR EXPANSION	-$103
														Subtotal = $1,382,930

Issue Date FY: 2024 ( Subtotal = $2,333,866 )
2024	2024	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	002	11	4/23/2024	NON-COMPETING CONTINUATION	$171,734
2024	2024	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	001	11	2/23/2024	NON-COMPETING CONTINUATION	$1,852,814
2024	2024	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	003	11	9/11/2024	NON-COMPETING CONTINUATION	$309,318
2024	2023	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	000	10	1/23/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,333,866

Issue Date FY: 2023 ( Subtotal = $3,520,032 )
2023	2023	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	001	10	3/24/2023	NON-COMPETING CONTINUATION	$2,982,169
2023	2023	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	003	10	8/23/2023	NON-COMPETING CONTINUATION	$377,188
2023	2023	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	000	9	1/13/2023	SUPPLEMENT FOR EXPANSION	$25,675
2023	2023	QUEENS UNIVERSITY AT KINGSTON	99 UNVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	002	10	5/5/2023	NON-COMPETING CONTINUATION	$135,000
														Subtotal = $3,520,032

Issue Date FY: 2022 ( Subtotal = $3,425,845 )
2022	2022	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	000	9	4/1/2022	NON-COMPETING CONTINUATION	$1,715,284
2022	2022	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	001	9	8/16/2022	NON-COMPETING CONTINUATION	$1,710,561
														Subtotal = $3,425,845

Issue Date FY: 2021 ( Subtotal = $3,066,187 )
2021	2021	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	002	8	9/17/2021	NON-COMPETING CONTINUATION	$435,000
2021	2021	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	001	8	2/26/2021	NON-COMPETING CONTINUATION	$2,631,187
2021	2020	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON			CAN	Cancer Treatment Research	000	7	2/26/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $3,066,187

Issue Date FY: 2020 ( Subtotal = $2,475,134 )
2020	2020	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	001	7	9/3/2020	NON-COMPETING CONTINUATION	$318,000
2020	2020	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	000	7	2/28/2020	NON-COMPETING CONTINUATION	$2,157,134
														Subtotal = $2,475,134

Issue Date FY: 2019 ( Subtotal = $1,820,005 )
2019	2019	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	004	6	8/26/2019	COMPETING CONTINUATION	$265,124
2019	2019	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	000	6	4/2/2019	COMPETING CONTINUATION	$1,554,881
2019	2019	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	003	6	6/28/2019	COMPETING CONTINUATION	$2,567,173
2019	2018	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	002	5	6/28/2019	NON-COMPETING CONTINUATION	-$2,407,344
2019	2017	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	001	4	6/28/2019	NON-COMPETING CONTINUATION	-$159,829
														Subtotal = $1,820,005

Issue Date FY: 2018 ( Subtotal = $2,407,344 )
2018	2018	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	001	5	9/11/2018	NON-COMPETING CONTINUATION	$630,706
2018	2018	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	000	5	2/28/2018	NON-COMPETING CONTINUATION	$1,776,638
														Subtotal = $2,407,344

Issue Date FY: 2017 ( Subtotal = $2,966,563 )
2017	2017	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	001	4	8/28/2017	NON-COMPETING CONTINUATION	$500,500
2017	2017	QUEEN'S UNIVERSITY AT KINGSTON	99 UNIVERSITY AVE	KINGSTON	ON	K7L 3N5		CAN	Cancer Treatment Research	000	4	3/2/2017	NON-COMPETING CONTINUATION	$2,466,063
														Subtotal = $2,966,563

Issue Date FY: 2016 ( Subtotal = $2,484,122 )
2016	2016	QUEENS UNIVERSITY	ABRAMSKY HALL, 3RD FLOOR	KINGSTON, ONTARIO				CAN	Cancer Treatment Research	001	3	9/8/2016	NON-COMPETING CONTINUATION	$173,950
2016	2016	QUEENS UNIVERSITY	ABRAMSKY HALL, 3RD FLOOR	KINGSTON, ONTARIO				CAN	Cancer Treatment Research	000	3	4/1/2016	NON-COMPETING CONTINUATION	$2,310,172
														Subtotal = $2,484,122

Issue Date FY: 2015 ( Subtotal = $3,135,983 )
2015	2015	QUEENS UNIVERSITY	ABRAMSKY HALL, 3RD FLOOR	KINGSTON, ONTARIO				CAN	Cancer Treatment Research	000	2	3/18/2015	NON-COMPETING CONTINUATION	$3,023,059
2015	2015	QUEENS UNIVERSITY	ABRAMSKY HALL, 3RD FLOOR	KINGSTON, ONTARIO				CAN	Cancer Treatment Research	001	2	9/9/2015	NON-COMPETING CONTINUATION	$112,924
														Subtotal = $3,135,983

Issue Date FY: 2014 ( Subtotal = $3,314,491 )
2014	2014	QUEENS UNIVERSITY	ABRAMSKY HALL, 3RD FLOOR	KINGSTON, ONTARIO				CAN	Cancer Treatment Research	001	1	9/15/2014	NEW	$291,432
2014	2014	QUEENS UNIVERSITY	ABRAMSKY HALL, 3RD FLOOR	KINGSTON, ONTARIO				CAN	Cancer Treatment Research	000	1	5/6/2014	NEW	$3,023,059
														Subtotal = $3,314,491

Grand Total All Awards = $32,332,502

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

Award Number: U10CA180863

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/06/2014

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer